Elegant Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 07-07-2024
- Paid Up Capital ₹ 2.00 M
as on 07-07-2024
- Company Age 36 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.60 Cr
as on 07-07-2024
- Satisfied Charges ₹ 2.21 Cr
as on 07-07-2024
- Revenue -55.43%
(FY 2023)
- Profit 46.86%
(FY 2023)
- Ebitda 22.43%
(FY 2023)
- Net Worth -325.20%
(FY 2023)
- Total Assets 19.26%
(FY 2023)
About Elegant Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹2.60 Cr. The company has closed loans amounting to ₹2.21 Cr, as per Ministry of Corporate Affairs (MCA) records.
Koteswara Yechuri, Seetha Subramaniyam, Bharatkumar Ostawal, and One other member serve as directors at the Company.
- CIN/LLPIN
U02423KA1988PTC009345
- Company No.
009345
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Aug 1988
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Hubli, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Elegant Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajashekar Pattanashetti  | Managing Director | 24-Dec-1997 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Koteswara Yechuri | Director | 13-Jan-2022 | Current |
| Seetha Subramaniyam | Director | 13-Jan-2022 | Current |
| Bharatkumar Ostawal | Director | 24-Dec-1997 | Current |
Financial Performance of Elegant Drugs.
Elegant Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 55.43% decrease. The company also saw a substantial improvement in profitability, with a 46.86% increase in profit. The company's net worth observed a substantial decline by a decrease of 325.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elegant Drugs?
In 2023, Elegant Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ariston Tek Solutions Private LimitedActive 16 years 11 monthsSeetha Subramaniyam is a mutual person
Rich `N' Rich Finance And Holdings LimitedActive 32 years 4 monthsKoteswara Yechuri is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 13 Nov 2009 | ₹2.60 Cr | Open |
Punjab National Bank Creation Date: 15 Sep 2008 | ₹1.35 M | Satisfied |
Punjab National Bank Creation Date: 31 May 2006 | ₹1.30 M | Satisfied |
How Many Employees Work at Elegant Drugs?
Elegant Drugs has a workforce of 8 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elegant Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elegant Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.